glp-1/gip/glucagon receptor agonist Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data The Effects of Dual GLP-1/GIP

Recently, to ensure the safety of GLP-1 RA on sarcopenia, a clinical randomized multicenter trial of bimagrumab, an antibody blockade of activin type II receptor inhibitor, alone or in addition to subcutaneous semaglutide is now ongoing (NCT05616013) [113]

Through systematic analysis of clinical trials, meta-analyses, and emerging evidence from landmark studies like SELECT, this paper evaluates whether GLP-1 agonists represent a transformative breakthrough or an overhyped intervention with significant limitations

Here are four of the most promising candidates: The anti-aging med The drug: BioAge Labs azelaprag is a drug that mimics the activity of apelin, a natural hormone secreted during exercise that helps regulate metabolism and promotes muscle regeneration

Some researchers have highlighted post-treatment study findings that have shown that people tend to suffer from a high risk of weight regain after stopping these drugs

Shared decision-making should take place, considering their current health status

doi: 10.1080/14656566.2019.1571040 122 GenoveseSMannucciECerielloA